Abbott Q3 Revenue Rises 14.5% to $13.01 Billion

Abbott Laboratories reported Q3 2026 revenue of $13.01B, up 14.5% YoY, slightly above estimates. Adjusted EPS matched expectations at $1.42, while GAAP EPS fell to $0.53. Diagnostics revenue surged 46.7% due to Exact Sciences acquisition. Abbott plans to spin off its Nutrition business by late 2027 and narrowed its full-year adjusted EPS guidance to $5.50–$5.55.

Original reporting
Published Oct 21, 2026, 12:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 3:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Abbott Q3 Revenue Rises 14.5% to $13.01 Billion — source image
Decision brief

The 30-second read

$ABTBearishHigh
01

Why it matters

The earnings beat and guidance stability are likely to generate buying interest, though GAAP EPS weakness may cause some caution.

02

Market read

Abbott's earnings surprise provides a clear short-term trading catalyst for the stock and its sector.

03

What to watch

Nutrition spin‑off plans may introduce execution risk and dilute focus on core businesses.

Relevance 9/10Novelty 9/10Timing: after-hours

Background

Abbott Laboratories is a diversified healthcare company with segments in diagnostics, medical devices, nutrition, and pharmaceuticals.

Company-level read

Ticker impact

$ABTBearishHigh confidence
Context

Abbott reported Q3 2026 revenue of $13.01B, up 14.5% YoY, beating estimates and provided updated EPS guidance.

Expected impact

potential upside as market prices in the revenue beat and unchanged full-year EPS outlook

Evidence & confidence

Large-cap earnings surprise with a solid beat on revenue and maintained guidance typically drives short-term buying pressure.

Market effects

Strong diagnostics growth may boost the broader healthcare equipment sector.

U.S. healthcare stocks could see modest gains following Abbott's beat.

Limited to investors tracking large-cap U.S. pharma and diagnostics companies.

Counterpoint

GAAP EPS decline and modest guidance narrowing could signal underlying margin pressure.

Key entities

  • Abbott Laboratories

    U.S.-listed healthcare conglomerate reporting Q3 2026 results.

Related articles

$PHGMed

New Study Shows How Hybrid Imaging Can Guide Coronary Treatment Decisions

Conavi Medical (TSXV: CNVI, OTCQB: CNVIF) received FDA 510(k) clearance for its hybrid imaging system, combining IVUS and OCT. The company reported first U.S. commercial placement, early clinical benefits, and extended credit facilities. Peer-reviewed research supports hybrid imaging for coronary treatment decisions. Conavi aims to expand physician adoption and hospital placements.

$ABTMed

Here's How Abbott's EP Business Is Shaping Up for the Rest of 2026

Abbott's (ABT) Medical Devices segment saw 8% sales growth in Q3 2026, driven by Electrophysiology (EP) products. EP sales grew mid-to-high-teens globally and over 20% in the U.S. Volt PFA catheter adoption accelerated post-U.S. launch. Abbott received FDA approval for TactiFlex Duo and CE Mark for Amulet 360. Japan launch expected in Q4. LAA market weakness is a headwind. Thermo Fisher (TMO) and Insulet (PODD) also reported Q3 earnings.

$ABTMed

Can UltiSynq Lead Boost Abbott's Cardiac Rhythm Management Business?

Abbott's UltiSynq defibrillation lead received FDA and CE Mark approvals, backed by successful trial results. The device aims to improve cardiac rhythm management, with 98.5% successful implantation and 97.5% complication-free rate at three months. Abbott also received FDA's breakthrough device designation. Medtronic and Boston Scientific provided updates on their cardiac devices. Abbott shares have declined 12.2% over the past year, trading at a forward P/S of 3.60X.

$ABTMedAI 9/10

Abbott Touts Favorable Outcomes In Cardiovascular Device Trials

Abbott Laboratories (ABT) presented positive clinical trial results for two cardiovascular devices at a conference. The Amulet 360 LAA Occluder showed 96.3% complete closure in patients, with low complication rates. The SonicForce System achieved 97% procedural success in treating calcified coronary arteries. ABT shares rose 2.55% to $108.91.